Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Eukaryotic Gene Expression
Facteur d'impact: 1.841 Facteur d'impact sur 5 ans: 1.927 SJR: 0.649 SNIP: 0.516 CiteScore™: 1.96

ISSN Imprimer: 1045-4403
ISSN En ligne: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v16.i3.30
pages 233-252

Functional Implications of BRCA1 for Early Detection, Prevention, and Treatment of Breast Cancer

Virna Dapic
Risk Assessment, Detection and Intervention Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612
Alvaro N. A. Monteiro
Risk Assessment, Detection and Intervention Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612; and Department of Interdisciplinary Oncology, College of Medicine, University of South Florida, Tampa, FL 33612


The tumor suppressor gene BRCA1 was positionally cloned in 1994. During the last 12 years, several lines of evidence have implicated BRCA1 in the maintenance of genome integrity, regulation of transcriptionn, and chromatin remodeling, suggesting that it has multiple biological roles. Germline mutations in BRCA1 confer a 56%−80% lifetime risk for breast cancer and a 15%−60% lifetime risk for ovarian cancer in women. And preliminary evidence suggests that BRCA1-linked breast and ovarian tumors behave differently from sporadic tumors, justifying a tailored approach to these cancers. Although several gaps still remain in our knowledge, it is possible to use information from basic research to illuminate clinical decisions and improve the prospects of mutation carriers. Along similar lines, genetic data derived from the clinical setting are also instrumental in determining which biochemical functions of BRCA1 contribute to its tumor suppressor actions. In this article, we explore the functional implications of BRCA1 for genetic testing (early detection), prevention, and therapy.

Articles with similar content:

Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan
Breast Cancer and Ovarian Cancer Genetics
Journal of Long-Term Effects of Medical Implants, Vol.15, 2005, issue 5
Richard Edlich, Kathryne L. Winters, Kant Y. Lin
Breast Cancer and Ovarian Cancer Genetics: An Update
Journal of Environmental Pathology, Toxicology and Oncology, Vol.27, 2008, issue 4
William B. Long III, Richard Edlich, Margot E. Chase, Catherine L. Cross, Kant Y. Lin, Courtney A. Wack
Yin Yang 1 in Human Cancer
Critical Reviews™ in Oncogenesis, Vol.16, 2011, issue 3-4
Richard Byers, Khimara Naidoo, Sarah Nicholson, Helen Whitehouse
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Carlos L. Arteaga, Brent N. Rexer